Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 22

recruiting
3 970
countries
28
conditions
2 124

10 522 trials match your criteria

Study on the Effects of Xenon and Oxygen on Brain Injury and Recovery in Patients with Aneurysmal Subarachnoid Hemorrhage in Intensive Care

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen

Study Comparing Clindamycin to Rifampicin and Drug Combination for Patients with Prosthetic Joint Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Clindamycin

Study on Ravulizumab for Children Aged 6 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ravulizumab

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Study on Early Diffuse Cutaneous Systemic Sclerosis: Comparing Stem Cell Transplantation with Cyclophosphamide, Filgrastim, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Filgrastim

Study on the Effectiveness and Safety of Ademetionine with Antidepressants for Patients with Major Depressive Disorder

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ademetionine

B-cell lymphoma

Recruiting

Study of TranspoCART19 Infusion for Patients with Relapsed or Refractory B-cell Lymphoma Using Genetically Modified T Lymphocytes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab

Study on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.